EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021

Khaylen Mistry iD, Polly Jeffrey iD, Nick J Levell iD, Oliver Kennedy iD, Kathryn Richardson iD, Paul Craig, Chloe Bright iD, Siobhan Taylor, John Ragan, Dimitrios Karponis iD, Joanna Pethick iD, Katrina Lavelle iD und 5 weitere

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljaf351 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Khaylen Mistry und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Norfolk and Norwich University Hospitals Foundation Trust, Norwich, UK. Hauptthemen laut MEDLINE: Melanoma, Proto-Oncogene Proteins B-raf, Skin Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inadequacy of testing for melanoma BRAF status results in delayed access to systemic therapy. BRAF mutations and their association with patient/tumour characteristics and survival is poorly understood.

Objectives

To report national data from England on the frequency of molecular BRAF testing; the association of patient/tumour characteristics with BRAF mutations; and the treatment and survival of patients with BRAF mutations.

Methods

This national retrospective cohort study identified all new melanomas and molecular BRAF testing in England diagnosed from 2016 to 2021 using population-based data from the National Disease Registration Service. Multivariate logistic regression determined the association between BRAF testing with patient/tumour characteristics and BRAF genotype with patient/tumour characteristics. Age-standardized net survival analysed melanoma-specific mortality by BRAF genotype.

Results

Of new cases of melanoma, 14% (n = 13 138/91 415) had a BRAF test registered. The proportion of successfully tested tumours that were BRAF-mutated was 34% (n = 4424/13 012). The West Midlands tested the highest proportion of cutaneous tumours (23%; n = 1783/7901) vs. the lowest in Yorkshire and the Humber (11%; n = 856/7760). Female patients [odds ratio (OR) 0.82, 95% confidence interval (CI) 0.79–0.86] and those aged > 80 years (OR 0.88, 95% CI 0.83–0.93) were less likely to be tested for BRAF mutations. BRAF mutations were associated with female gender (OR 1.16, 95% CI 1.07–1.26). Patients aged > 80 (OR 0.36, 95% CI 0.32–0.40) had lower odds of having BRAF-mutated tumours. Patients with BRAF mutations had a lower 5-year net survival [55.9% (95% CI 52.7–59.2) vs. BRAF wildtype 5-year net survival 62.2% (95% CI 60.1-64.5)], particularly in stage II disease.

Conclusions

This study presents the largest dataset on national melanoma BRAF status published to date. The data highlight geographical and demographic variations in BRAF testing and the impact of BRAF mutations on survival rates, particularly in patients with stage II disease. This highlights the critical role of consistent, early and accurate testing to ensure equal care, guide treatment decisions and understand prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaProto-Oncogene Proteins B-rafSkin NeoplasmsHumansFemaleMaleEnglandMiddle AgedAgedRetrospective StudiesMutationAdultAged, 80 and overYoung AdultAdolescentGenetic Testing

Substanzen

Proto-Oncogene Proteins B-rafBRAF protein, human

Autor:innen und Institutionen

  • Department of Dermatology, Norfolk and Norwich University Hospitals Foundation Trust, Norwich, UK.
  • Norwich Medical School, University of East Anglia, Norwich, UK.
  • National Disease Registration Service, NHS England, Leeds, UK.
  • Department of Oncology, The Christie NHS Foundation Trust, Manchester, UK.
  • University of Manchester, Manchester, UK.
  • Norwich Epidemiology Centre, University of East Anglia, Norwich, UK.

ORCID-Profile: Khaylen Mistry, Polly Jeffrey, Nick J Levell, Oliver Kennedy, Kathryn Richardson, Chloe Bright, Dimitrios Karponis, Joanna Pethick, Katrina Lavelle, Fiona McRonald, Sally Vernon, Paul Lorigan, Zoe C Venables

Förderung

  • Cancer Research UK

Zitieren

APA

Mistry, K., Jeffrey, P., Levell, N. J., Kennedy, O., Richardson, K., Craig, P., Bright, C., Taylor, S., Ragan, J., Karponis, D., Pethick, J., Lavelle, K., McRonald, F., Hardy, S., Vernon, S., Lorigan, P., & Venables, Z. C. (2025). A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf351

Vancouver

Mistry K, Jeffrey P, Levell NJ, Kennedy O, Richardson K, Craig P, et al. A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf351

BibTeX
@article{Mistry2025,
  author = {Mistry, Khaylen and Jeffrey, Polly and Levell, Nick J and Kennedy, Oliver and Richardson, Kathryn and Craig, Paul and Bright, Chloe and Taylor, Siobhan and Ragan, John and Karponis, Dimitrios and Pethick, Joanna and Lavelle, Katrina and McRonald, Fiona and Hardy, Steven and Vernon, Sally and Lorigan, Paul and Venables, Zoe C},
  title = {A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England from 2016 to 2021},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljaf351}
}
Kostenlos starten →